Reduced survival of type 2B von willebrand factor, irrespective of large multimer representation or thrombocytopenia

Haematologica

Volumn 95, Issue 8, 2010, Pages 1366-1372

  Casonato, Alessandra ^a   Gallinaro, Lisa ^a   Cattini, Maria Grazia ^a   Pontara, Elena ^a   Padrini, Roberto ^a   Bertomoro, Antonella ^a   Daidone, Viviana ^a   Pagnan, Antonio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Large VWF multimers; Type 2B thrombocytopenia; Type 2B VWD; Von willebrand factor; VWF half life

Indexed keywords

COLLAGEN; DESMOPRESSIN; GLYCOPROTEIN IB; VON WILLEBRAND FACTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE MUTATION; HALF LIFE TIME; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

BLOOD PLATELETS; FAMILY HEALTH; FEMALE; HALF-LIFE; HUMANS; KINETICS; MALE; MUTATION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR;

EID: 77956021805     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019927     Document Type: Article

References (40)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem. 1998;67:395-424.
2. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol. 2003;10(2):142-9.
3. Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood. 1981;58(2):387-97.
4. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44):41059-63.
5. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991;88(33):774-82.
6. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589-600.
7. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA. 1990;87(16):6306-10.
8. Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood. 1987;70(4):895-904.
9. Sadler JE, Budde U, Eikenboom CJ, Favaloro EJ, Hill FG, Holmberg L, et al.; Working Party on von Willebrand disease classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4(10):2103-14.
10. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med. 1980;302(19):1047-51.
11. Ruggeri ZM. Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost. 2004;2(1):2-6.
12. Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J Clin Invest. 1991; 87(4):1220-6.
13. Rendal E, Penas N, Larrabeiti B, Pérez A, Vale A, Lopez-Fernandez MF, et al. Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship. Ann Hematol. 2001; 80(6):354-60.
14. Gralnick HR, Williams SB, McKeown LP, Rick ME, Maisonneuve P, Jenneau C, et al. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest. 1985;76(4):1522-9.
15. De Marco L, Mazzucato M, Grazia Del Ben M, Budde U, Federici AB, Girolami A, et al. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. J Clin Invest. 1987;80(2):475-82.
16. Weiss HJ, Sussman II. A new von Willebrand factor variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full complement of multimers. Blood. 1986;68(1):149-56.
17. Casonato A, Sartori MT, De Marco L, Girolami A. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost. 1990;64(1):117-20.
18. Casonato A, Steffan A, Pontara E, Zucchetto A, Rossi C, De Marco L, et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost. 1999; 81(2):224-8.
19. Casonato A, Sartori MT, Bertomoro A, Fede T, Vasoin F, Girolami A. Pregnancyinduced worsening of thrombocytopenia in a patient with type IIB von Willebrand's disease. Blood Coagul Fibrinolysis. 1991;2(1):33-40.
20. Hultin MB, Sussman II. Postoperative thrombocytopenia in type IIB von Willebrand disease. Am J Hematol. 1990; 33(1):64-8.
21. Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, et al. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb Haemost. 2007;6(1):90-6.
22. Holmberg L, Berntorp E, Donner M, Nilsson IM. Von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood. 1986; 68(3):668-72.
23. Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, et al. A novel von Willebrand factor mutation (I1372S) associated with type 2Blike von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb Haemost. 2007;98(6):1182-7.
24. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111(7):3540-5.
25. Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99(1):180-4.
26. Sztukowska M, Gallinaro L, Cattini MG, Pontara, E, Sartorello F, Daidone V, et al. Von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Brit J Haematol. 2008;143(1):107-14.
27. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10): 4979-85.
28. Casonato A, De Marco L, Mazzuccato M, De Angelis V, De Roia D, Fabris F, et al. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma. Blood. 1989;74(6):2028-33.
29. Gibaldi M, Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker 1975.
30. Menache D, Aronson DL, Darr F, Montgomery RR, Gill JC, Kessler CM, et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study. Br J Haematol. 1996; 94(4):740-5.
31. Goodeve AC, Eikenboom JCJ, Ginsburg D, Hilbert L, Mazurier C, Peake IR, et al. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost. 2001;85(5):929-31.
32. Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: true 2B, tricky 2B, or not 2B. What are the modifiers of the phenotype¿ Sem Thromb Hemost. 2008;34(6):520-31.
33. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279(13):12102-9.
34. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest. 1986;77(3):947-51.
35. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort sturdy of 67 patients. Blood. 2009;113(3):526-34.
36. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrate of ADAMTS13 under fluid shear stress. Blood. 2008;111(2):651-7.
37. Rayes J, Hommais A, Legendre P, Tout H, Veyradier A, Obert B, et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand to ADAMTS-13. J Thromb Haemost. 2006;5(2):321-8.
38. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033-9.
39. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA. 2004;101(29):10578-83.
40. Wang ZJ, Onwuzurike N, Callaghan MU, Rajpurkar M, Chitlur M, Lusher JM. Decreased clearance of von Willebrand factor in a patient with type 2B von Willebrand disease following development of immune thrombocytopenia. Pediatr Blood Cancer. 2008;51(3):416-8.